Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

September 11, 2024 9:00 AM

FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jim Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, presented at the H.C. Wainwright 26 th Annual Global Investment Conference. The video webcast of...

Read more

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

September 11, 2024 8:15 AM

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / OS Therapies (NYSE American:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced positive data in animal models of ovarian cancer for its first therapeutic candidate developed based upon its proprietary tunable Antibody Drug Conjugate (tADC) platform. The first therapeutic candidate leverages a folate...

Read more

Enalare Therapeutics Receives Additional Funding From BARDA to Further Advance the Development of Agnostic Respiratory Stimulant (ENA-001)

September 10, 2024 8:00 AM

PRINCETON, NJ / ACCESSWIRE / September 10, 2024 / Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today announced that it has received additional funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and...

Read more

Altius Bioventures Launches The CGT Industry Atlas, Mapping out the Cell and Gene Therapy Technology Innovation Landscape

September 10, 2024 8:00 AM

Altius Bioventures is pleased to announce the release of its CGT Industry Atlas, a comprehensive guide outlining its view of the cell and gene therapy technologies landscape, from starting material collection to therapy manufacturing and clinical delivery. The CGT Industry Atlas categorizes the sector into seven core elements, each representing a critical component within the cell and gene therapy ecosystem."The CGT Industry Atlas is designed to...

Read more

Vicore Initiates the Global, Randomized Phase 2b ASPIRE Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis

September 10, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / September 10, 2024 / Vicore Pharma Holding (STO:VICO)ASPIRE is a global Phase 2b trial measuring change in FVC from baseline over 52 weeks, the established regulatory endpoint.ASPIRE will enroll 270 patients across 14 countries, including the United States, and will allow patients to remain on background nintedanib standard of care therapy.The advancement of buloxibutid into late-stage development is supported by...

Read more

The Center for Immunology Science and Immunology Diagnostics Announce a Major Breakthrough Discovery: DNA-Based Proof of the Disease of Fibromyalgia

September 9, 2024 8:00 AM

Groundbreaking Study Confirms Fibromyalgia as a True Medical Condition with 100% Accuracy Using Unique DNA Genomic Signatures, Offering New Hope for Objective Diagnosis and Treatment.​LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / A medical study recently published in the highly ranked and prestigious medical and science journal, NATURE-Scientific Reports, (Springer Nature (2024) 14:3949), found that 100% of patients who received a positive...

Read more

BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024

September 9, 2024 1:20 AM

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV)BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients.Promising efficacy data in combination with KEYTRUDA® (pembrolizumab) with partial responses in relapsed and refractory advanced melanoma and leiomyosarcoma patients.Favorable safety profile with minimal adverse events and no dose-limiting toxicities.Lund, Sweden...

Read more

BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

September 9, 2024 1:20 AM

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV)Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (CTCL) have been observed in the single agent part of the Phase 2a study. Three other patients in the cohort were considered non-evaluable.All patients had progressed after standard therapy. The three responding patients had received 9, 3 and 3...

Read more

Medical University of Graz Selects the HALO AP(R) Digital Pathology Platform to Deliver Comprehensive Diagnostics

September 6, 2024 8:00 AM

The Diagnostics & Research Institute for Pathology at the Medical University of Graz, a leader in personalized patient care and one of the largest hospitals in Austria, has selected the HALO AP® digital pathology platform from Indica Labs to deliver primary diagnostics. The enterprise digital pathology platform was selected alongside Aperio GT 450 scanners from Leica Biosystems for quality, performance, functionality, and usability.The intuitive...

Read more

Tanvex BioPharma Forging Strategic Alliance With Bora Pharmaceuticals

September 5, 2024 12:05 PM

Combining Tanvex's biosimilar development expertise and U.S. FDA-licensed commercial-scale facility in San Diego, California, with Bora's extensive global CDMO capabilities, the alliance aims to provide comprehensive solutions to biologics CDMO customers around the world.SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Tanvex BioPharma ("Tanvex" or the "Company"), a contract development and manufacturing organization (CDMO) for biologics and a...

Read more

Cambridge Isotope Laboratories, Inc. Expands 13C Production Capacity With North Star Project

September 5, 2024 9:00 AM

TEWKSBURY, MA / ACCESSWIRE / September 5, 2024 / Cambridge Isotope Laboratories, Inc. (CIL), the global leader in 13Cand 13C urea production, is excited to announce the startup of its North Star project, significantly increasing the company's production capabilities.CIS AerialCIS Aerial The North Star project commenced in mid-2020 as the world's largest 13C production cascade. After the complex build of phase one finished in March 2024, CIL...

Read more

Prolocor and Slingshot Biosciences Announce Publication of 'Assessing Prognosis by Quantifying FcγRIIa on Fixed Platelets' in Bioanalysis

September 5, 2024 8:00 AM

The Prolocor pFCG® test measures the expression of a specific protein on the platelet surface which this study demonstrates is a reliable prognostic tool to help assess the risk of thrombosis (a key cause of heart attack & stroke) and inform clinical decision making.This novel test is performed on fixed platelets and uses TruCytes cell mimics (produced by Slingshot Biosciences) as an internal control to improve precision, accuracy, and linear...

Read more

Moolec Confirms US Harvest and Promising Yields for Plant-Grown Products GLASO(TM) and Piggy Sooy(TM) in October

September 5, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / September 5, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today the harvest confirmation of US campaigns for genetically engineered plant-grown products GLASO™ and Piggy Sooy™ during October 2024. GLASO™ and Piggy Sooy™ US Harvest Announcement GLASO™ (gamma-linolenic acid -GLA- in safflower oil) campaign located in Idaho consists of 600 planted...

Read more

Adolore BioTherapeutics Announces Issuance of First Japanese Patent Covering CA8* Long-Acting Local Analgesic Therapies to Treat Chronic Pain

September 4, 2024 8:00 AM

Patent and novel, potent CA8* nonopioid analgesic licensed by Adolore BioTherapeutics from the University of MiamiCompany is advancing development of rdHSV-CA8* gene therapy delivered intracellularly for the treatment of chronic osteoarthritis (OA) knee pain toward an IND with NIH/NINDS UH3 HEAL funding up to and including the First-in-Human clinical studyDELRAY BEACH, FL / ACCESSWIRE / September 4, 2024 / Adolore BioTherapeutics ("Adolore" or...

Read more

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024 9:00 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.Presentation Date:...

Read more

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

September 3, 2024 9:00 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Sandy Prietto has joined the Company as Vice President of Marketing. Ms. Prietto brings many years of medical device marketing experience including successful new product launches at Endologix and Edwards Lifesciences."In addition to the wealth of marketing experience and...

Read more

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

August 29, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with aggregate gross proceeds of $5 million, for the issuance and sale of an aggregate of...

Read more

FluoGuide A/S Publishes Interim Report for the Period January - June 2024

August 29, 2024 3:05 AM

KØBENHAVN, DENMARK / ACCESSWIRE / August 29, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 29 August 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 30 June 2024. The Q2 report is available as an attached document to this press release and on FluoGuide's website.In Q2 2024, the Company successfully completed a directed share issue, raising proceeds SEK 60 million to support the...

Read more

Vicore Announces Presentations at the European Respiratory Society Congress 2024

August 29, 2024 2:10 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / August 29, 2024 / Vicore Pharma Holding (STO:VICO)Sessions at the upcoming ERS include an oral presentation of additional Phase 2a AIR trial data of buloxibutid in IPFAdditional presentations include preclinical and translational data reflecting the impact of buloxibutid's upstream mechanism of actionVicore will additionally present on aspects of the Phase 2b ASPIRE trial designed to maximize patient...

Read more

BioInvent International AB: Interim Report January-June 2024

August 29, 2024 2:10 AM

LUND, SWEDEN / ACCESSWIRE / August 29, 2024 / BioInvent International (STO:BINV)"The presentation of promising results from our two lead drug candidates at the ASCO Annual Meeting showcased their potential as first-in-class immunomodulatory agents and kicked off a data-rich period for BioInvent where we expect to report results from all six of our clinical programs." - Martin Welschof, CEO of BioInvent.EVENTS IN THE SECOND QUARTER• (R)...

Read more